Kužma Martin, Vaňuga Peter, Pávai Dušan, Killinger Zdenko, Hans Didier, Binkley Neil, Payer Juraj, Jackuliak Peter
5th Department of Internal Medicine, Comenius University Faculty of Medicine, University Hospital Bratislava, Bratislava, Slovakia.
Department of Endocrinology, National Institute of Endocrinology and Diabetology, Lubochna, Slovakia.
Front Endocrinol (Lausanne). 2024 Dec 12;15:1448566. doi: 10.3389/fendo.2024.1448566. eCollection 2024.
Acromegaly is associated with increased vertebral fracture (VF) risk regardless of bone mineral density (BMD). However, the vertebral trabecular compartment is still low; a possible contributor to this may be impaired glucose metabolism (GM) which frequently complicates acromegaly. Additionally, soft tissue thickness may confound bone imaging in acromegaly patients.
This study aims to assess the association of GM with BMD, trabecular bone score adjusted for BMI (TBS), and trabecular bone score adjusted for tissue thickness (TBS) among acromegaly subjects.
A cross-sectional study was performed among 70 consecutive acromegaly patients (24 male/46 female, aged 55.1 years) divided in two subgroups: abnormal GM ( = 35) and normal GM ( = 35). Using DXA, BMD, TBS, TBS, and VF screening were performed.
In all subjects, TBS was higher (mean 9.5%) than TBS. Abnormal GM subjects had lower TBS (1.166 ± 0.15) than normal GM subjects (1.232 ± 0.12; < 0.05). No between-group difference in TBS or BMD was observed. In a multiple regression model, the best predictor of TBS was HbA1c ( = 0.002). None of the DXA measures or GM parameters was a significant predictor of VF ( = 7).
The abnormal GM acromegaly subjects had lower TBS than those with normal GM. TBS was higher than TBS, and no between-group difference based on GM status was observed. TBS was significantly associated with GM parameters, notably HbA1c. The relationship of TBS with GM parameters may imply an effect of GM on trabecular bone microstructure in patients with acromegaly; a further study is indicated.
无论骨矿物质密度(BMD)如何,肢端肥大症都与椎体骨折(VF)风险增加相关。然而,椎体小梁部分仍然较低;造成这种情况的一个可能原因可能是葡萄糖代谢(GM)受损,这在肢端肥大症中经常出现。此外,软组织厚度可能会混淆肢端肥大症患者的骨成像。
本研究旨在评估肢端肥大症患者中GM与BMD、根据体重指数(BMI)调整的小梁骨评分(TBS)以及根据组织厚度调整的小梁骨评分(TBS)之间的关联。
对70例连续的肢端肥大症患者(24例男性/46例女性,年龄55.1岁)进行了横断面研究,分为两个亚组:GM异常(=35)和GM正常(=35)。使用双能X线吸收法(DXA)进行BMD、TBS、TBS和VF筛查。
在所有受试者中,TBS高于TBS(平均9.5%)。GM异常的受试者TBS(1.166±0.15)低于GM正常的受试者(1.232±0.12;<0.05)。未观察到TBS或BMD的组间差异。在多元回归模型中,TBS的最佳预测指标是糖化血红蛋白(HbA1c)(=0.002)。DXA测量值或GM参数均不是VF的显著预测指标(=7)。
GM异常的肢端肥大症患者的TBS低于GM正常的患者。TBS高于TBS,未观察到基于GM状态的组间差异。TBS与GM参数显著相关,尤其是HbA1c。TBS与GM参数之间的关系可能意味着GM对肢端肥大症患者小梁骨微结构有影响;需要进一步研究。